drugset / Trial / NCT05833035

A Study in Healthy Men to Test How BI 1291583 is Processed in the Body

NCT05833035

Phase 1 Completed 8 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

The main objective of this trial is to * Assess the mass balance and total recovery of \[14C\]-radioactivity in urine and faeces following a dose of BI 1291583 (C-14) * Provide plasma and urine samples for pharmacokinetic investigations * Provide plasma, urine, and faeces samples for metabolic profiling and structural identification of metabolites

Timeline

Start
2023-04-24
Primary completion
2023-07-05
Completion
2023-07-05

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1291583 Unknown Oral

Indications

No indication recorded.